These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26364412)

  • 21. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Osteoporosis. Improving bone and muscle performance].
    MMW Fortschr Med; 2010 Dec; 152(48):36. PubMed ID: 21222333
    [No Abstract]   [Full Text] [Related]  

  • 23. I was prescribed alendronate (Fosamax) for bone loss a year ago, when I was 55. I just got the results of my recent bone density scan and I'm puzzled by the results. Why would it show a good improvement in the spine but no so much on my hip? How long do I have to wait to see results on my bone density?
    Health News; 2006 May; 12(5):16. PubMed ID: 16685754
    [No Abstract]   [Full Text] [Related]  

  • 24. NOFSA statement on generic bisphosphonates.
    Hough S
    S Afr Med J; 2006 Sep; 96(9):758-60. PubMed ID: 17068638
    [No Abstract]   [Full Text] [Related]  

  • 25. Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.
    Heervä E; Huilaja L; Leinonen P; Peltonen S; Peltonen J
    Calcif Tissue Int; 2014 Jun; 94(6):608-12. PubMed ID: 24390519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
    de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
    N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the current anti-osteoporotic therapy paradigm good enough?
    Fisher AA; Davis MW
    J Am Geriatr Soc; 2006 Dec; 54(12):1960-1, author reply 1961-3. PubMed ID: 17198519
    [No Abstract]   [Full Text] [Related]  

  • 29. [Alendronate and resorptive hypercalciuria].
    Arrabal-Polo MA; Arrabal-Martin M; Zuluaga-Gomez A
    Med Clin (Barc); 2011 Sep; 137(7):333. PubMed ID: 21543092
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum ionic fluoride concentrations are significantly decreased after treatment with alendronate in patients with osteoporosis.
    Sato H; Tanno K; Muro-oka G; Itai K
    Clin Chim Acta; 2011 Nov; 412(23-24):2146-9. PubMed ID: 21839730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
    Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
    J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent topics in the treatment of osteoporosis in Japan].
    Miki T
    Nihon Ronen Igakkai Zasshi; 2007 Mar; 44(2):165-7. PubMed ID: 17527008
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drug therapy for prevention of falls and fractures].
    Ringe JD
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination treatment in osteoporosis. Basic treatment plus specific osteoporosis medication].
    Ringe JD
    Med Monatsschr Pharm; 2009 Apr; 32(4):137-40. PubMed ID: 19445270
    [No Abstract]   [Full Text] [Related]  

  • 36. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
    Kishimoto M; Oishi A; Motojima S
    N Engl J Med; 2006 Nov; 355(20):2156; author reply 2157. PubMed ID: 17108350
    [No Abstract]   [Full Text] [Related]  

  • 39. Secondary prophylaxis of osteoporotic fractures in an orthogeriatric service.
    Kenealy H; Paul S; Walker K; Garg A
    Australas J Ageing; 2011 Mar; 30(1):41. PubMed ID: 21395941
    [No Abstract]   [Full Text] [Related]  

  • 40. [Osteoporosis treatment evaluation with desoxypiridinoline urine detection in postmenopause patients].
    Solís-Cabrera BH; Del Carmen Ramírez-Benítez M; Cocotle-Ronzón Y; Moreno-Todd M; Soto-Cid AH
    Rev Med Inst Mex Seguro Soc; 2009; 47(1):25-8. PubMed ID: 19624960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.